Clinical Protocol to Investigate the Efficacy of Amlexanox vs. Placebo for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Amlexanox (Primary)
- Indications Non-alcoholic fatty liver disease; Obesity; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 31 Oct 2017 Planned End Date changed from 1 Oct 2016 to 1 Dec 2019.
- 31 Oct 2017 Status changed from completed to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated